US FDA approves Scholar Rock's muscle weakness drug
11/09/2026 22:24
US FDA approves Scholar Rock's muscle weakness drug Sept 11 (Reuters) - The U.S. Food and Drug Administration on Friday approved Scholar Rock's SRRK.O therapy to treat a rare genetic condition that causes muscle weakness.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
Recent news on Novartis AG
See all newsNovartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx